



Kang'ombe House, 5<sup>th</sup> Floor  
P.O. Box 30742  
Lilongwe 3, Malawi  
Tel: +265 (0)111 772 466/529/530  
+265 (0) 999 970 269  
Email- [compcom@comesa.competition.org](mailto:compcom@comesa.competition.org)



Common Market for Eastern  
and Southern Africa

15 March 2024

## **CCC Merger Inquiry Notice No. 10 of 2024**

### **Notice of Inquiry into the Proposed Acquisition of Control by AsterRx Holdings Over Allmed Medical Care Holdings Ltd.**

It is hereby notified in terms of Article 26(6) of the COMESA Competition Regulations (the “**Regulations**”) that the COMESA Competition Commission (the “**Commission**”), after receiving a notification in terms of Article 24 of the Regulations regarding the proposed acquisition of control by AsterRx Holdings (“**AsterRx**” or the “**acquirer**”) over Allmed Medical Care Holdings Ltd. (“**Allmed**” or “**target**”), intends to embark on an inquiry in terms of Article 26 of the Regulations.

The parties have submitted that AsterRx will acquire 85% of the issued share capital of Allmed.

The parties have submitted that AsterRx, a company registered in Mauritius whose registered office is on the 5<sup>th</sup> floor, Ebene Esplanade, 24 Bank Street, Cybercity, Ebene, Mauritius, is a special-purpose vehicle ultimately wholly owned and controlled by Alta Semper Ilera Fund I L.P (“**Alta Fund**”), a limited liability partnership incorporated in Mauritius and managed by Alta Semper Capital LLP (“**Alta Capital**” together “**Alta**” or the “**acquiring group**”). The acquirer group is active in the distribution of pharmaceutical products and personal care products and retail sales of pharmaceutical products and personal care products in the Common Market. Within the Common Market, the acquiring group operates in Kenya and Uganda.

The parties have submitted that Allmed is a company incorporated under the laws of England and Wales, whose registered office is on the 5<sup>th</sup> floor, building 7 Chiswick Park, 566 Chiswick High Road, London, England, W4 5yg. The target along with its subsidiaries (the “**target group**”) is active in the manufacturing and supply of medical devices for dialysis, such as Dialyzers, Blood Lines, Fistula Needles, Acid Concentrates, and Bicarbonate Cartridges as well as pharmaceuticals required for dialysis including intravenous solutions and heparin sodium. Within the Common Market, the target group operates in Egypt, Ethiopia, Kenya, Sudan, Tunisia, Uganda, and Zambia.

The Commission will, under the provisions of the Regulations, determine, among other things, whether the proposed transaction is likely to substantially prevent or lessen competition within the Common Market and whether the proposed transaction is or

would be contrary to the public interest as provided for under Article 26 of the Regulations.

In view of this, the Commission hereby gives notice to all interested stakeholders, including competitors, suppliers, and customers of the parties to the proposed transaction to submit written representations to the Commission with regard to the subject matter of the proposed inquiry by emailing them to: [mdebessay@comesacompetition.org](mailto:mdebessay@comesacompetition.org). All written representations should be sent to the Commission not later than **5 April 2024**.

If you wish to seek further details and/or clarifications on any aspect of this proposed transaction or need assistance you may get in touch with **Mr. Mengistu Debessay, Senior Analyst, Competition Division** on Tel: +265 111 772 466 or [mdebessay@comesacompetition.org](mailto:mdebessay@comesacompetition.org).

All written representations submitted to the Commission will be treated with the strictest confidentiality and will only be used for the purpose of this inquiry.